DRB1 Antibody

What are the recommended applications and dilutions for HLA-DRB1 antibodies in laboratory research?

HLA-DRB1 antibodies such as the 15862-1-AP can be utilized across multiple experimental applications with specific recommended dilutions for optimal results. Methodologically, researchers should consider the following application-specific dilutions:

It is essential to note that optimal dilutions may be sample-dependent, requiring assay-specific optimization. For immunohistochemistry applications, antigen retrieval with TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 can serve as an alternative .

What cell and tissue types are most appropriate for HLA-DRB1 antibody validation?

For effective experimental design, researchers should prioritize cell lines and tissues with confirmed HLA-DRB1 expression. Validation studies have demonstrated positive Western blot detection in multiple specimen types including:

• Raji cells (B lymphocyte cell line)

• Human spleen tissue

• A375 cells (melanoma cell line)

• Daudi cells (Burkitt's lymphoma cell line)

For immunoprecipitation experiments, Raji cells have shown reliable results. In immunohistochemistry applications, human tonsillitis tissue provides appropriate positive control material .

What are the storage requirements for maintaining HLA-DRB1 antibody activity?

Proper storage methodology is critical for maintaining antibody functionality. HLA-DRB1 antibodies should be stored at -20°C in appropriate buffer systems. The 15862-1-AP antibody specifically utilizes PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 as its storage buffer. Under these conditions, the antibody remains stable for one year after shipment. Importantly, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling protocols. Small volume preparations (20μl) contain 0.1% BSA as a stabilizing agent .

How should researchers design HLA-DRB1 genotyping experiments for immunological studies?

Methodologically robust HLA-DRB1 genotyping requires specialized approaches. The recommended procedure involves:

• Extraction of genomic DNA from whole blood collected in EDTA tubes using systems such as Maxwell 16 with appropriate DNA purification kits

• Implementation of high-resolution DNA-based typing methods such as LABType HD Class II DRB1 Typing Test

• Utilization of reverse sequence-specific oligonucleotide probes with Luminex technology

• Amplification of target DNA (HLA-DRB1 gene) using group-specific biotinylated primers for detection with streptavidin R-phycoerythrin conjugate

• Denaturation and hybridization of PCR products to complementary DNA probes conjugated to fluorophores

• Detection of bound DNA on the Luminex system

• Analysis using specialized software (e.g., HLA Fusion Software) to map reaction patterns to published HLA gene sequences

This methodological approach ensures accurate HLA-DRB1 allele assignment according to specific amino acid sequences at positions 72-74 and further subdivision by amino acid groups at positions 70 and 71.

What controls should be implemented when studying HLA-DRB1 associations with autoantibody production?

When investigating HLA-DRB1 associations with autoantibody responses, methodological rigor requires appropriate experimental controls. Researchers should:

• Include ethnically matched control cohorts of substantial size (as exemplified by the EIRA study with 4,392 White European descent patients and a separate cohort of 1,199 Southeast Asian origin patients)

• Implement quantitative analysis of antibody levels, including those falling below diagnostic thresholds

• Conduct validation in independent cohorts (such as the replication study in 4,109 patients with RA of White European origin described in the literature)

• Control for population stratification covariates in statistical analyses

• Evaluate both shared epitope alleles and non-shared epitope alleles (recent data revealed previously overlooked associations with non-shared epitope alleles HLA-DRB1*09 and *15)

• Assess dose effects through homozygosity analysis (e.g., the doubling of risk observed with DRB1*07:01 homozygosity suggesting causality)

How should researchers interpret contradictory findings in HLA-DRB1 and antibody association studies?

Researchers facing contradictory results in HLA-DRB1 association studies should implement a methodological framework that:

• Evaluates the study population size and composition (the statistical power of large cohorts like the 4,392-patient EIRA study provides more reliable results than smaller investigations)

• Considers ethnic variation (associations should be tested across multiple ethnicities as demonstrated in studies finding HLA-DRB1*09 and *15 associations independent of ethnicity)

• Assesses quantitative rather than merely qualitative antibody measurements

• Examines linkage disequilibrium patterns (for example, DRB107:01 and DQA102:01 show strong linkage disequilibrium but can be distinguished from variation at DRB3 and DQB1 flanking loci)

• Tests for heterozygous versus homozygous effects, which can reveal dose-dependent relationships

• Employs statistical methods that control for population stratification

How can HLA-DRB1 antibodies be effectively used in multiplex immunoassay systems?

For advanced multiplex immunoassay applications involving HLA-DRB1:

• Optimize antibody concentrations specifically for multiplex environments, which typically require higher dilutions than traditional single-target assays

• Evaluate cross-reactivity extensively against other HLA class II molecules to ensure specificity

• Consider bead-based technologies (Luminex) which have demonstrated success in HLA-DRB1 research

• Implement appropriate blocking strategies to minimize background signal

• Establish comprehensive validation protocols using multiple cell lines (Raji, A375, Daudi cells have been successfully used)

• Pair with appropriate detection systems, such as streptavidin R-phycoerythrin conjugates

• Incorporate multiplexed cytokine profiling when studying autoimmune conditions, as cytokine measurements by multiplex bead array technology provide valuable complementary data

What methodological approaches best distinguish between HLA-DRB1 allele-specific antibody responses?

Distinguishing allele-specific antibody responses requires sophisticated methodological approaches:

• Employ high-resolution HLA typing methods that can differentiate specific amino acid sequences at positions 70-74 of the HLA-DRB1 molecule

• Implement statistical analyses that calculate odds ratios for alloimmunization to different antigens (this approach has revealed associations such as anti-E with DRB109 [OR=3.7] and anti-S with DRB107 [OR=8.7])

• Consider sex-stratified analyses, as demonstrated by the observed female-to-male ratio of 3.8 in antibody formation studies

• Evaluate multiple antibody formation patterns in relation to DRB1 susceptibility genes (research shows HLA-DRB1*15 is present in approximately 40% of multiple responders compared to 25% in single-antibody responders)

• Assess epitope-specific responses rather than general antibody positivity

• Consider combinatorial effects of specific alleles, as multiple antibody formation appears less dependent on particular HLA restriction genes

What are the most effective quality control measures for ensuring reproducibility in HLA-DRB1 antibody-based research?

Ensuring reproducibility in HLA-DRB1 antibody research requires rigorous quality control methodology:

• Validate antibody specificity through multiple detection methods (WB, IHC, IF/ICC, IP) using standardized protocols

• Confirm reactivity across diverse sample types (the 15862-1-AP antibody demonstrates reactivity with human samples and cited reactivity with human and mouse specimens)

• Document molecular weight validation (27-30 kDa observed for HLA-DRB1 corresponds to the calculated molecular weight of 30 kDa for the 266 amino acid protein)

• Implement reference identification systems (RRID identifiers like AB_1639897 enable precise antibody tracking)

• Record comprehensive antibody metadata including host/isotype information (Rabbit/IgG), class (Polyclonal), and purification method (Antigen affinity purification)

• Validate with multiple test cells/tissues and implement appropriate antigen retrieval methodologies

• Establish standardized titration protocols for each testing system to obtain optimal results

How do HLA-DRB1 alleles influence autoantibody development in rheumatoid arthritis?

HLA-DRB1 alleles demonstrate complex relationships with autoantibody development in rheumatoid arthritis:

• Beyond the classic shared epitope (SE) associations, recent quantitative analyses reveal that non-SE alleles HLA-DRB1*09 and *15 exhibit significant associations with anti-citrullinated peptide/protein antibody (ACPA) levels

• These associations appear independent of ethnicity, as demonstrated in studies of both European (4,392 patients) and Southeast Asian (1,199 patients) cohorts

• The associations extend beyond diagnostic thresholds, affecting the quantitative levels of anti-cyclic citrullinated peptide IgG antibodies even when below cutoff values

• These findings suggest a previously overlooked regulatory role for the HLA locus in controlling ACPA levels that extends beyond shared epitope-defined gene variants

• Methodologically, these insights were only possible through quantitative rather than qualitative antibody analysis and large-scale multi-ethnic cohort studies

What role do HLA-DRB1 alleles play in multiple antibody formation in transfusion recipients?

HLA-DRB1 alleles demonstrate distinct patterns in multiple antibody formation scenarios:

• HLA-DRB1 restriction appears to play a crucial role in initial red blood cell (RBC) antibody response, but multiple antibody formation follows different immunological pathways

• Multiple antibody formation is only in a minority of cases associated with the presence of multiple DRB1 susceptibility genes

• HLA-DRB1*15 is present in approximately 40% of multiple responders compared to roughly 25% in single-antibody responders and the control population

• This suggests HLA-DRB1*15 may represent a susceptibility phenotype that enhances formation of multiple RBC antibody specificities

• Studies confirmed known associations and identified new ones, such as anti-E with DRB109 (OR=3.7) and anti-S with DRB107 (OR=8.7)

• This pattern indicates that while initial immunization may require specific HLA restriction elements, subsequent responses may operate through different immunological mechanisms

How should researchers design case-control studies to investigate HLA-DRB1 associations in neurological conditions?

Methodologically sound case-control studies investigating HLA-DRB1 in neurological conditions should:

• Incorporate multiethnic cohorts with appropriate sample sizes (exemplified by the study of anti-LGI1 encephalitis with 269 patients and 1,359 controls)

• Employ both four-digit HLA sequencing and genome-wide association single-nucleotide polymorphism typing imputation (with high concordance rates, e.g., 0.99)

• Test significance of primary and secondary associations using appropriate statistical methods (χ², Fisher exact tests, or logistic regression)

• Control for population stratification covariates where applicable

• Evaluate linkage disequilibrium patterns (as demonstrated in the finding that DRB107:01 and DQA102:01 are in strong linkage disequilibrium but associated with disease independent of variation at flanking HLA loci)

• Assess homozygosity effects to determine causality (homozygosity for DRB1*07:01 was associated with a doubling of risk [OR=2.1, p=0.010] suggesting a causal relationship)

• Conduct cross-ethnicity validation to confirm that associations are not population-specific

What are the most common technical challenges when working with HLA-DRB1 antibodies and how can they be resolved?

Researchers frequently encounter several technical challenges when working with HLA-DRB1 antibodies:

• Antigen Retrieval Issues: For IHC applications, recommended antigen retrieval with TE buffer pH 9.0 may be insufficient in some tissues. Alternative approaches include:

  • Testing citrate buffer pH 6.0 as specified in methodological guidelines

  • Extending retrieval time incrementally while monitoring tissue integrity

  • Optimizing retrieval temperature between 95-100°C

• Cross-Reactivity Concerns: Due to high homology among HLA class II molecules, validate specificity through:

  • Testing on multiple cell lines with known HLA-DRB1 expression profiles

  • Confirming the observed molecular weight matches the expected 27-30 kDa range

  • Performing peptide competition assays to confirm epitope specificity

• Variable Signal Intensity: When signal strength is inconsistent:

  • Titrate antibody concentration within the recommended range (1:50-1:500 for IHC, 1:500-1:2000 for WB)

  • Extend primary antibody incubation time at 4°C

  • Incorporate signal amplification systems appropriate to the detection method

  • Ensure sample contains sufficient target protein (confirmed positive samples include Raji cells, human spleen tissue)

How can researchers optimize Western blot protocols specifically for HLA-DRB1 detection?

Optimizing Western blot protocols for HLA-DRB1 detection requires methodological refinement:

• Sample Preparation:

  • Use RIPA buffer supplemented with protease inhibitors for efficient extraction

  • Include phosphatase inhibitors if investigating post-translational modifications

  • Maintain cold chain throughout sample processing

• Gel Electrophoresis Parameters:

  • Utilize 10-12% polyacrylamide gels for optimal resolution of the 27-30 kDa HLA-DRB1 protein

  • Load 20-50 μg of total protein per lane depending on expression levels

  • Include positive control lysates (Raji cells, human spleen tissue) in parallel

• Transfer Conditions:

  • Implement semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

  • Use PVDF membranes rather than nitrocellulose for higher protein retention

  • Confirm transfer efficiency with reversible protein stains

• Antibody Incubation:

  • Begin with 1:1000 dilution for primary antibody incubation

  • Extend primary antibody incubation to overnight at 4°C

  • Optimize blocking with 5% non-fat dry milk in TBST

• Detection System:

  • Enhanced chemiluminescence systems provide optimal sensitivity

  • For multiplexed detection, use fluorescent secondary antibodies with spectrally distinct fluorophores

  • Document exposure times for reproducibility

What methodological approaches can resolve discrepancies in HLA-DRB1 genotyping results?

When facing discrepancies in HLA-DRB1 genotyping results, researchers should implement a systematic troubleshooting methodology:

• Sequencing Verification:

  • Implement four-digit HLA sequencing as the gold standard verification method

  • Compare with genome-wide association single-nucleotide polymorphism typing imputation (with concordance rates ≥0.99)

  • Sequence ambiguous regions directly using Sanger sequencing

• Sample Quality Assessment:

  • Evaluate DNA purity (A260/A280 ratio) and concentration

  • Assess DNA integrity through gel electrophoresis

  • Extract fresh DNA using validated systems (such as Maxwell 16 with appropriate DNA purification kits)

• Technical Replication:

  • Perform technical replicates using independent DNA extractions

  • Utilize alternative typing methodologies (PCR-SSP, PCR-SSOP, SBT)

  • Compare results across different laboratory platforms

• Reference Material Inclusion:

  • Include well-characterized reference samples with known HLA-DRB1 genotypes

  • Participate in proficiency testing programs for external validation

  • Utilize international cell line standards with established genotypes

• Bioinformatic Approach:

  • Apply multiple allele assignment algorithms

  • Evaluate raw data quality scores and genotype calling confidence metrics

  • Consider haplotype phasing to resolve ambiguous results based on population-specific linkage disequilibrium patterns